TICKERNERD
Menu
KYTXKYTXHealthcare · Biotechnology

KYTX Stock Forecast: Kyverna Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$8.17
+1.11% on the day

The 6 Wall Street analysts covering Kyverna Therapeutics, Inc. hold a median 12-month price target of $32 — +291.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 41 of 100 as at 15 Aug 2026 — in the lower half.

Market cap
$505.3M
Ticker Nerd rank
41 / 100
Median analyst target
$32
Analysts covering
6
Total return, dividends reinvested
1W
+2.6%
1M
+2.9%
YTD
−13.1%
1Y
+130.8%
From 52W high
−27.4%
From 52W low
+147.6%
$3
$11
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

KYTX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Kyverna Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
41 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
83
Growth
76
Revisions
67
Size
54
Accruals
48
Value
30
Quality
26
Volatility
19
Issuance
10

Momentum (83): The shares have been drifting up relative to others.

Issuance (10): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

KYTX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on KYTX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15$20$25$30$35Oct 25Jan 26Apr 26Jul 26KYTXHigh $33Median $32Low $25

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says6 analysts
6 Buy0 Hold0 Sell
Low $25Median $32High $33

The green dot is the last close — the median target sits +291.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
3 June 2026HC Wainwright & Co.ReiteratesBuy$25
15 May 2026HC Wainwright & Co.MaintainsBuy—
13 May 2026JP MorganMaintainsOverweight—
23 Apr 2026HC Wainwright & Co.ReiteratesBuy—
16 Dec 2025Wells FargoMaintainsOverweight—
4 Dec 2025Morgan StanleyMaintainsOverweight—
30 Oct 2025Wells FargoMaintainsOverweight—
27 Oct 2025HC Wainwright & Co.MaintainsBuy—
8 Oct 2025Wells FargoMaintainsOverweight—
29 Aug 2025HC Wainwright & Co.MaintainsBuy—
20 Aug 2025William BlairInitiatesOutperform—
27 May 2025HC Wainwright & Co.UpgradeBuy—
3 Apr 2025HC Wainwright & Co.MaintainsNeutral—
1 Apr 2025Morgan StanleyMaintainsOverweight—
20 Nov 2024HC Wainwright & Co.MaintainsNeutral—
15 Nov 2024Wells FargoMaintainsOverweight—
10 Oct 2024UBSInitiatesBuy—
19 Sept 2024HC Wainwright & Co.ReiteratesNeutral—
15 Aug 2024HC Wainwright & Co.MaintainsNeutral—
31 July 2024JP MorganMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. KYTX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

KYTX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
2
Fundamentals

Kyverna Therapeutics, Inc. (KYTX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.2×

Cheaper than 86% of US stocks

Price / sales
—
Price / book
2.5×

Cheaper than 40% of US stocks

EV / EBITDA
−2.2×

Cheaper than 72% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−87.2%

Higher than 15% of US stocks

Return on assets
−44.5%

Higher than 9% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

KYTX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
KYTXKyverna Therapeutics, Inc.$505.3M
41
BLSMBlossomhill Therapeutics, Inc.$495.8M
0
ENTXEntera Bio Ltd.$500.4M
46
OABIOmniAb, Inc.$486.6M
93
RLMDRelmada Therapeutics, Inc.$503.5M
69
PRTAProthena Corp. Plc$476.9M
98
MPLTMapLight Therapeutics, Inc.$512.8M
7

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Kyverna Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest KYTX news & analysis

Kyverna Therapeutics: Market Holding Flat Despite Progress To Approval

Seeking Alpha · 13 Aug 2026positive

Kyverna Therapeutics is advancing mivocabtagene autoleucel for autoimmune diseases, with a rolling BLA submission underway targeting completion in late 2026 and potential approval by mid-2027. Updated KYSA-8 data showed all 26 patients remained off chronic immunotherapies at 16 weeks with 81% mobility improvement, and key phase 2/3 data in myasthenia gravis are expected soon.

Why it matters — For KYTX watchers, this item highlights regulatory and clinical momentum toward a first approval in stiff person syndrome, with upcoming myasthenia gravis data representing a near-term catalyst.

Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results

GlobeNewsWire · 11 Aug 2026positive

Kyverna Therapeutics reported pipeline progress and second quarter 2026 financial results. The FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation for miv-cel in non-active secondary progressive multiple sclerosis (naSPMS), based on compelling clinical data, expanding the therapy's potential across neuroimmunology.

Why it matters — The RMAT designation for miv-cel in naSPMS signals regulatory recognition of the therapy's clinical data and broadens Kyverna's pipeline opportunity in neuroimmunology.

Kyverna Therapeutics: 'Strong Buy' On ElevateBio Manufacturing Deal And RA Program Advancement

Seeking Alpha · 29 July 2026positive

Kyverna Therapeutics is described as a 'Strong Buy' as its candidate miv-cel advances in SPS, gMG, and refractory RA with robust clinical data. A rolling BLA submission for miv-cel in SPS is underway targeting completion by Q4 2026, and a manufacturing agreement with ElevateBio has been secured to support commercialization.

Why it matters — KYTX watchers would care because the ElevateBio manufacturing deal supports supply for miv-cel's potential U.S. and global commercialization, while the rolling BLA submission marks a key regulatory milestone for the pipeline.

FAQ

Frequently asked questions about KYTX stock

What is the KYTX stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Kyverna Therapeutics, Inc. have a median 12-month price target of $32, with estimates ranging from $25 to $33. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is KYTX stock a buy right now?

Of the 6 analysts covering Kyverna Therapeutics, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Kyverna Therapeutics, Inc. 41 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank KYTX?

As at 15 Aug 2026, Kyverna Therapeutics, Inc. ranks 41 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (83 of 100).

Will KYTX stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +291.7% from the last close, and Ticker Nerd's factor model ranks Kyverna Therapeutics, Inc. 41 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the KYTX stock forecast for 2030?

No analyst covering Kyverna Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KYTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $25 to $33 over the next 12 months.

How has KYTX stock performed over the past year?

Kyverna Therapeutics, Inc. returned +130.8% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Kyverna Therapeutics, Inc. do?

Kyverna Therapeutics Inc. is a biotechnology company pioneering innovative therapeutics focusing on autoimmune diseases.

What is the latest news on KYTX?

The most recent item we track (Seeking Alpha, 13 Aug 2026): "Kyverna Therapeutics: Market Holding Flat Despite Progress To Approval". Kyverna Therapeutics is advancing mivocabtagene autoleucel for autoimmune diseases, with a rolling BLA submission underway targeting completion in late 2026 and potential approval by mid-2027. Updated KYSA-8 data showed all 26 patients remained off chronic immunotherapies at 16 weeks with 81% mobility improvement, and key phase 2/3 data in myasthenia gravis are expected soon.

Company

About Kyverna Therapeutics, Inc.

Kyverna Therapeutics Inc. is a biotechnology company pioneering innovative therapeutics focusing on autoimmune diseases. Kyverna's primary goal is to harness cell therapies to target and suppress the immune system's harmful autoimmune responses. The company's unique approach lies in its development of engineered T cell therapies designed to reset the immune system's balance, potentially providing long-lasting relief from debilitating conditions. With operations driven by cutting-edge research and development, Kyverna Therapeutics is at the forefront of a transformative field impacting the healthcare sector. In the broader market, this biotech firm represents a significant advance in the ongoing search for effective, less invasive therapies for chronic autoimmune disorders, tapping into a growing demand for solutions that can improve quality of life for millions globally. Headquartered in the United States, Kyverna Therapeutics continues to leverage innovative science to revolutionize treatment paradigms for autoimmune conditions.

CEO Mr. Warner Biddle · 149 employees · United States · https://kyvernatx.com